Vetmedica: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Vetmedica
Largest movements
- Current investments +€10,000
new in 2025: €10,000
- Receivables within one year -€7,994
down €7,994 (-22.9%), from €34,894 to €26,900
of which Trade receivables: -€7,378
- Cash +€5,804
up €5,804 (+16.6%), from €34,986 to €40,791
mainly Net result for the year (+€20,680) and Receivables within one year (+€7,994)
- Deferred charges and accrued income +€2,049
new in 2025: €2,049
- Reserves +€20,680
up €20,680 (+47.3%), from €43,694 to €64,374
- Tax, wage and social debts -€11,198
down €11,198 (-51.5%), from €21,731 to €10,533
- Gross operating margin -€31,717
down €31,717 (-52.5%), from €60,434 to €28,718
- Taxes -€8,915
down €8,915 (-53.1%), from €16,803 to €7,888
- Financial charges +€972
up €972 (+1,730%), from €56 to €1,028
- Financial income +€762
up €762 (+135%), from €565 to €1,327
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €69,881 | €79,740 | +€9,860 | +14.1% |
| Current assets | 29/58 | €69,881 | €79,740 | +€9,860 | +14.1% |
| Amounts receivable within one year | 40/41 | €34,894 | €26,900 | -€7,994 | -22.9% |
| Trade receivables | 40 | €13,510 | €6,132 | -€7,378 | -54.6% |
| Other amounts receivable | 41 | €21,384 | €20,768 | -€617 | -2.9% |
| Current investments | 50/53 | - | €10,000 | +€10,000 | |
| Cash at bank and in hand | 54/58 | €34,986 | €40,791 | +€5,804 | +16.6% |
| Deferred charges and accrued income | 490/1 | - | €2,049 | +€2,049 | |
| Total equity and liabilities | 10/49 | €69,881 | €79,740 | +€9,860 | +14.1% |
| Equity | 10/15 | €46,694 | €67,374 | +€20,680 | +44.3% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Reserves | 13 | €43,694 | €64,374 | +€20,680 | +47.3% |
| Distributable reserves | 133 | €43,694 | €64,374 | +€20,680 | +47.3% |
| Amounts payable | 17/49 | €23,186 | €12,366 | -€10,820 | -46.7% |
| Amounts payable within one year | 42/48 | €23,186 | €12,366 | -€10,820 | -46.7% |
| Trade debts | 44 | €1,455 | €1,833 | +€378 | +25.9% |
| Suppliers | 440/4 | €1,455 | €1,833 | +€378 | +25.9% |
| Taxes, remuneration and social security | 45 | €21,731 | €10,533 | -€11,198 | -51.5% |
| Taxes | 450/3 | €21,731 | €10,533 | -€11,198 | -51.5% |
| Other operating charges | 640/8 | €446 | €449 | +€3 | +0.6% |
| Gross operating margin | 9900 | €60,434 | €28,718 | -€31,717 | -52.5% |
| Operating profit (loss) | 9901 | €59,988 | €28,268 | -€31,719 | -52.9% |
| Financial income | 75/76B | €565 | €1,327 | +€762 | +135% |
| Recurring financial income | 75 | €565 | €1,327 | +€762 | +135% |
| Financial charges | 65/66B | €56 | €1,028 | +€972 | +1,730% |
| Recurring financial charges | 65 | €56 | €1,028 | +€972 | +1,730% |
| Profit (loss) for the period before taxes | 9903 | €60,497 | €28,568 | -€31,929 | -52.8% |
| Income taxes | 67/77 | €16,803 | €7,888 | -€8,915 | -53.1% |
| Profit (loss) for the period | 9904 | €43,694 | €20,680 | -€23,015 | -52.7% |
| Profit (loss) for the period to be appropriated | 9905 | €43,694 | €20,680 | -€23,015 | -52.7% |
Source: filed annual accounts (NBB), financial years ended 30 June 2024 and 30 June 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 21 October 2026 via checked.be.